Malaria Consortium

Waiting for malaria chemoprevention treatment in Burkina Faso (Susan Schulman/Malaria Consortium)

You do not have Javascript enabled. Some elements of this website may not work correctly.

Malaria Consortium fights malaria by distributing preventive drugs via seasonal malaria chemoprevention programs

Donate with Effective Altruism Funds Donate Directly Website

Fast Facts

  • Malaria Consortium works in Africa and Asia to prevent, control and treat malaria and other communicable diseases
  • It’s recommended for it’s seasonal malaria chemoprevention programs (SMC’s), through which it distributes preventive anti-malarial drugs to children under 5
  • SMC is cost effective and supported by a strong base of evidence through randomized controlled trials

Malaria Consortium fights malaria by distributing preventive drugs via seasonal malaria chemoprevention programs.

How it works

  • Whilst Malaria Consortium works on a variety of measures to combat communicable diseases, it is recommended by GiveWell for their Seasonal malaria chemoprevention programs (SMC’s).
  • SMC involves giving antimalarial medicine to children in areas of highly seasonal transmission during the malaria season.
  • Up to four treatment courses are given over four months, providing protection up to one month after the end of the final course, and Malaria Consortium aims to provide four months of treatment
  • Community health workers (CHWs), supported by Malaria Consortium, deliver treatments by going door-to-door or by treating people in a community at a fixed point

Why we recommend it

There is good evidence that SMC programs are a cost-effective way to prevent malaria. GiveWell have tentatively estimated that the cost for a four-month SMC treatment provided through Malaria Consortium, taking into account costs of research and of the governments who assist with programs, is around $9.37[1].

Malaria Consortium is also impressive since it has conducted studies in most of the countries where it has worked to see how successfully it has reached the children targeted. These studies have found high rates of reach; 87% received treatment for one month and 46% for the maximum four months[2].

The intervention of SMC is expected to have a large amount of room for more funding globally, and GiveWell expect that Malaria Consortium in particular is well placed to productively absorb more funds.

For more information about why Malaria Consortium is a considered a top charity, we’d recommend reading more on GiveWell’s website.


Footnotes

  1. See GiveWell's review, <http://www.givewell.org/charities/malaria-consortium#Cost_for_SMC_coverage> ↩︎

  2. See GiveWell's review, <http://www.givewell.org/charities/malaria-consortium#Roomformorefunding> ↩︎